Vall d’Hebron Barcelona Hospital Campus has celebrated its first PhD Day, a whole day of scientific activities created for and…
Josep Tabernero
Clarivate, a global leader in connecting people and organizations to intelligence to transform the world, has revealed its list of…
Josep Tabernero, Director of the Vall d’Hebron Institute of Oncology (VHIO) has been appointed chairman of the European consortium Cancer…
Results of the study FRESCO-2 show a statistically and clinically meaningful benefit with a favorable safety profile in patients with…
In recognition of multidisciplinary integrated cancer care, translational and clinical cancer research of excellence at the Vall d’Hebron University Hospital…
The New England Journal of Medicine publishes today the results of the SUNLIGHT study, a Phase III clinical trial comparing…
Futibatinib, an advanced FGFR inhibitor, has demonstrated effectiveness in impeding tumor growth among patients with FGFR-altered tumors. What is Intrahepatic…
We are delighted to announce that our Director Josep Tabernero is among the selected candidates for the American Association for…
The annual ASCO Symposium on Gastrointestinal Cancers took place from 19-21 January. Josep Tabernero, Director of VHIO, presented the results…
Recently published in Nature Reviews Gastroenterology & Hepatology*, a comprehensive Review focused on gastric cancer and gastro-oesophageal junction cancer (GC-GOJC)…
